<DOC>
	<DOCNO>NCT01583114</DOCNO>
	<brief_summary>This multicentre European double-blind , randomize control trial 2 parallel group ( 1 study medication , 1 placebo ) order analyse impact ACE inhibitor ( ACEi ) subject carry mutation yet develop DCM ( dilate cardiomyopathy ) . Objective trial : Study impact ACE inhibitor ( ACEi ) subject carry mutation ( leading genetic form heart failure ) yet develop DCM . Context . Dilated Cardiomyopathy ( DCM ) one lead cause Heart Failure due systolic dysfunction least 30 % DCM familial/genetic origin , usually autosomal dominant inheritance , underlie gene mutation increasingly identify . Familial Dilated Cardiomyopathy ( fDCM ) characterize age-related penetrance ( delayed-onset ) , mean cardiac expression disease ( echocardiographic abnormality ) usually absent long period progressively appear advanced age , usually 20 year age Hypothesis : ACEi may delay prevent occurrence DCM subject ( pre-clinical stage ) . Expected result : If hypothesis confirm , consequence , knowledge derive basic research ( gene identification DCM ) translate clinical practice ( early identification subject high risk develop heart failure predictive genetic test ) development new therapeutic management ( early ACEi ) help decrease morbidity mortality associate disease . This constitute paradigm development preventive medicine thanks development genetics cardiovascular field . Subjects concerned ≥18 year age ≤60 year , carry mutation responsible DCM preclinical stage disease . Total duration treatment ( perindopril versus placebo ) 3 year . A total number 200 participant enrol ( 100 group ) 7 centre .</brief_summary>
	<brief_title>PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy ACE Inhibitors</brief_title>
	<detailed_description>This study part broader research program , `` INHERITANCE '' ( INtegrated HEart Research In TrANslational genetics dilate Cardiomyopathies Europe ) research project , submit EU ( FP7 European Union , HEALTH-2009-2.4.2-3 : Translation basic knowledge inherit cardiomyopathy clinical practice ) accept 2009 ( Grant agreement n° 241924 , global coordinator : Pr Eloisa Arbustini , Pavia , Italy ) . - Precardia / clinical trial Principal Investigator : Dr Philippe Charron , Pitié Salpêtrière hospital , France - FP7 Global Inheritance network coordinator : Pr Eloisa Arbustini , Italia</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Perindopril</mesh_term>
	<criteria>Age : ≥18 year ≤60 year At least one family member clinical diagnosis dilate cardiomyopathy ( LVEF &lt; 45 % LVEDD &gt; 112 % ) consider burnout phase another cardiomyopathy ( HCM , ARVC ) . LV noncompaction may coexist DCM patient.NB : patient mutation LMNA gene , LVEDD may normal whereas EF markedly reduce , reduce LVEF mandatory ( LVEF &lt; 45 % ) . Carriers mutation identify family associate DCM , receive appropriate genetic counselling announcement genetic result . The mutation within family consider diseasecausing . No obvious DCM assess diagnostic criterion indicate elsewhere echocardiography ( WHO &amp; Mestroni et al . 1999 Mahon et al . 2005 : reference 3 9 ) : LVEF &lt; 45 % enlarge LVEDD ( &gt; 112 % predict value accord age , BSA ) . Presence minor LV abnormality : isolated LVEDD &gt; 112 % ( Henry Formula ) reduce systolic dysfunction : 45 % &lt; LVEF &lt; 55 % , assess echocardiography . Able provide inform consent , sign informed consent . Able understand accept study constraint For European country ( France Spain ) : participant ( ) medical health care coverage include research study Other disease factor cause minor LV abnormality , cardiotoxic treatment significant blood hypertension ( uncontrolled blood pressure significant hypertrophy echocardiography ) . Contraindication ACE inhibitor Participants already treat ACE inhibitor , sartan aldosterone receptor antagonist ( various reason arterial hypertension ) include study , unless drug period 6 week inclusion . Impaired renal function : estimate Glomerular Filtration Rate ( eGFR ) , use MDRD formula , &lt; 60 ml/mn/1.73m2 . Baseline serum potassium &gt; 5.5 mmol/L . Pregnant , parturient breastfeed woman woman childbearing potential effective contraception plan pregnancy . Participation another therapeutic trial previous 3 month Participants treat lithium Participant legal guardianship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>dilate cardiomyopathy</keyword>
	<keyword>heart failure</keyword>
	<keyword>genetics</keyword>
	<keyword>mutation carrier</keyword>
	<keyword>ACE treatment</keyword>
	<keyword>preclinical</keyword>
</DOC>